Literature DB >> 9047329

Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase.

P Masson1, P Legrand, C F Bartels, M T Froment, L M Schopfer, O Lockridge.   

Abstract

The atypical variant of human butyrylcholinesterase has Gly in place of Asp 70. Patients with this D70G mutation respond abnormally to the muscle relaxant succinyldicholine, experiencing hours of apnea rather than the intended 3 min. Asp 70 is at the rim of the active site gorge 12 A from the active site Ser 198. An unanswered question in the literature is why the atypical variant has a 10-fold increase in Km for compounds with a single positive charge but a 100-fold increase in Km for compounds with two positive charges. We mutated residues Asp 70, Trp 82, Trp 231, Glu 197, and Tyr 332 and expressed mutant enzymes in mammalian cells. Steady-state kinetic parameters for hydrolysis of butyrylthiocholine, benzoylcholine, succinyldithiocholine, and o-nitrophenyl butyrate were determined. The wild type and the D70G mutant had identical k(cat) values for all substrates. Molecular modeling and molecular dynamics suggested that succinyldicholine could bind in two consecutive orientations in the active site gorge; formation of one complex caused a conformational change in the omega loop involving Asp 70 and Trp 82. We propose the formation of three enzyme-substrate intermediates preceding the acyl-enzyme intermediate; kinetic data support this contention. Substrates with a single positive charge interact with Asp 70 just once, whereas substrates with two positive charges, for example succinyldithiocholine, interact with Asp 70 in two complexes, thus explaining the 10- and 100-fold increases in Km in the D70G mutant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047329     DOI: 10.1021/bi962484a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  A modular treatment of molecular traffic through the active site of cholinesterase.

Authors:  S A Botti; C E Felder; S Lifson; J L Sussman; I Silman
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

2.  Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase.

Authors:  P Masson; M T Froment; C F Bartels; O Lockridge
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Progress-curve analysis through integrated rate equations and its use to study cholinesterase reaction dynamics.

Authors:  Marko Goličnik
Journal:  J Mol Neurosci       Date:  2014-07       Impact factor: 3.444

4.  Tetramerization domain of human butyrylcholinesterase is at the C-terminus.

Authors:  R M Blong; E Bedows; O Lockridge
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

5.  Computational redesign of human butyrylcholinesterase for anticocaine medication.

Authors:  Yongmei Pan; Daquan Gao; Wenchao Yang; Hoon Cho; Guangfu Yang; Hsin-Hsiung Tai; Chang-Guo Zhan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

6.  cDNA cloning and characterization of a plant protein that may be associated with the harpinPSS-mediated hypersensitive response.

Authors:  C H Chen; H J Lin; M J Ger; D Chow; T Y Feng
Journal:  Plant Mol Biol       Date:  2000-07       Impact factor: 4.076

Review 7.  Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Authors:  Patrick Masson; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2009-12-11       Impact factor: 4.013

Review 8.  Rational design of an enzyme mutant for anti-cocaine therapeutics.

Authors:  Fang Zheng; Chang-Guo Zhan
Journal:  J Comput Aided Mol Des       Date:  2007-11-08       Impact factor: 3.686

9.  Characterization of butyrylcholinesterase from porcine milk.

Authors:  Ashima Saxena; Tatyana Belinskaya; Lawrence M Schopfer; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2018-06-15       Impact factor: 4.013

10.  An evaluation of the inhibition of human butyrylcholinesterase and acetylcholinesterase by the organophosphate chlorpyrifos oxon.

Authors:  Josephine Shenouda; Paula Green; Lester Sultatos
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-19       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.